Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma Clinical Trial

Official title:

Prediction of Recurrence Among Low Risk Endometrial Cancer Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04604613
• Other study ID #: PA12-0550
• Secondary ID: NCI-2020-07548PA
• Status: Recruiting
• Start date: November 8, 2012
• Est. completion date: December 31, 2026

Study information

• Verified date: February 2024
• Source: M.D. Anderson Cancer Center
• Contact: Shannon N Westin
• Phone: 713-794-4314
• Email: swestin[@]mdanderson.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to remove the uterus and/or cervix (hysterectomy). Having sentinel lymph node mapping performed may help researchers to see if the cancer has spread in patients with low risk endometrial cancer.

Description:

PRIMARY OBJECTIVE: I. Validate the use of a molecular panel of estrogen-induced genes to predict recurrence in low risk endometrial cancer. SECONDARY OBJECTIVES: I. Calculate the positive predictive value (PPV)/negative predictive value (NPV)/sensitivity (Sens)/specificity (Spec) of lymph node mapping to predict pelvic lymph node involvement. II. Correlate CA125 and HE4 levels with recurrence and to explore the use of other serum biomarkers to predict recurrence. III. Describe patterns of recurrence in a low risk patient population. IV. Determine if molecular panel can predict lymph node involvement in low risk endometrial cancer patients who undergo pelvic and para-aortic lymphadenectomy. V. Compare performance of molecular panel to the Mayo low risk criteria for prediction of lymph node involvement. VI. Compare performance of molecular panel to the high intermediate risk criteria from Gynecologic Oncology Group, trial 99 (GOG 99) for prediction of recurrence. VII. Determine the feasibility of lymph node mapping in this patient population. VIII. Determine the morbidity and mortality of lymph node dissection and mapping. OUTLINE: Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histologically confirmed low grade (grade 1-2) endometrioid type adenocarcinoma
• Candidate for surgery
• No evidence of deep invasion or peritoneal disease in patients that have undergone preoperative imaging
• Patients may have had prior hormonal treatment for the treatment of early endometrial neoplasia. Patients may not have had prior radiation or chemotherapy for treatment of endometrial cancer
• Patients must have a negative pregnancy if of childbearing potential

Exclusion Criteria:

• Histologically confirmed high grade endometrioid or non-endometrioid type endometrial cancer (including serous, clear cell, carcinosarcoma or any mixed tumor containing these cell types)
• Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
• Evidence of deep myometrial invasion, cervical involvement or peritoneal disease on preoperative imaging
• Prior treatment with radiation or chemotherapy for endometrial cancer
• Any contraindication to lymph node mapping

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Endometrioid
• Endometrial Neoplasms
• FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
• FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
• Recurrence

Intervention

Procedure:
• Bilateral Salpingectomy with Oophorectomy
Undergo standard of care bilateral salpingo-oophorectomy
• Biospecimen Collection
Undergo collection of blood and tissue samples
• Hysterectomy
Undergo standard of care hysterectomy

Other:
• Laboratory Biomarker Analysis
Correlative studies

Procedure:
• Lymph Node Mapping
Undergo sentinel lymph node mapping
• Sentinel Lymph Node Biopsy
Undergo sentinel lymph node biopsy

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year recurrence	Will validate a model's ability to predict 2-year recurrence in low-risk endometrial cancer patients.	At 2 years
Secondary	Predictive ability of lymph node mapping in pelvic lymph node involvement	Will calculate the sensitivity (true positive fraction [TPF]), specificity (1-false positive fraction [FPF]), positive predictive value (PPV), and negative predictive value (NPV) of lymph node mapping in predicting pelvic lymph node involvement, along with 2-sided 95% confidence intervals.	Up to 2 years
Secondary	Feasibility of lymph node mapping	Feasibility of lymph node mapping in this patient population will be determined after examining the TPF, FPF, PPV, and NPV.	Up to 2 years
Secondary	Morbidity and mortality prevalence associated with lymph node dissection	Morbidity and mortality prevalence associated with lymph node dissection and mapping will be calculated with 95% confidence intervals.	Up to 2 years
Secondary	Patterns of recurrence	Will determine which demographic and clinical traits are most associated with recurrence rate using proportional hazards models and with 2-year recurrence using logistic regression models. Will conduct univariate analyses using log-rank tests and Fisher's exact tests, in the case of categorical traits, and proportional hazards and logistic regression models, in the case of continuous traits. Will examine all traits for violations of the proportional hazards assumption (recurrence rate models), and will examine all continuous traits for functional form (recurrence and recurrence rate models). Will use the same methods to determine whether CA125 and HE4 is associated with recurrence and recurrence rate.	Up to 2 years
Secondary	Predictive ability of molecular panel in lymph node involvement	Will use Cartesian and Regression Tree Analysis and logistic regression to determine if the molecular panel can predict lymph node involvement. Will assess the use of the model by calculating sensitivity, specificity, PPV, and NPV. Additionally, will examine how often the results of the molecular panel model concur with the Mayo low risk criteria for prediction of lymph node involvement. All agreement statistics will be presented with their 95% confidence intervals.	Up to 2 years
Secondary	Predictive ability of marker panel in recurrence	Will examine how well the predictive ability of the marker panel agrees with the predictive ability of the high intermediate risk criteria from Gynecologic Oncology Group, trial 99 using this patient population. 95% confidence intervals will be calculated for all concordance statistics.	Up to 2 years

External Links

•   MD Anderson Cancer Center Website